A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors

Sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Study ID
NCT06926283
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • DXC008 — DRUG
    Cohort A: Once every 2 weeks (Q2W) with a cycle length of 14 days. Cohort B: Once every 3 weeks (Q3W) with a cycle length of 21 days.

Study Details

This is a phase I, open-label, first-in-human clinical study designed to evaluate the safety, tolerability, MTD, DLT, RP2D, the PK characteristics, preliminary anti-tumor activity, the immunogenicity of DXC008 in patients with prostate cancer and other solid tumors such as Ewing sarcoma.

Key Dates

First listed
Apr 13, 2025
Start date
May 15, 2025
Status verified
Nov 2025
Primary completion
Apr 30, 2030
Completion
Apr 30, 2030

Study Design

Enrollment
110 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: DXC008

Primary Outcome Measure

Number of participants that experienced dose limiting toxicities(DLTs) at given dose level. [ Time Frame: 28 days ]

Central Contacts

Find similar trials

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials

Related Studies